Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Faricimab, a bispecific antibody, simultaneously targets angiopoietin-2 and vascular endothelial growth factor-A (VEGF-A), and is utilized in research on diabetic macular edema (DME) [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | Inquiry | Inquiry | |
5 mg | Inquiry | Inquiry |
Description | Faricimab, a bispecific antibody, simultaneously targets angiopoietin-2 and vascular endothelial growth factor-A (VEGF-A), and is utilized in research on diabetic macular edema (DME) [1]. |
Synonyms | RG7716 |
Molecular Weight | N/A |
CAS No. | 1607793-29-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Faricimab 1607793-29-2 Angiogenesis Tyrosine Kinase/Adaptors VEGFR RG7716 RG 7716 RG-7716 inhibitor inhibit